Page last updated: 2024-12-11
novolimus
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
novolimus: belongs to the family of macrocyclic lactones with immunosuppressive and anti-proliferative properties [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9854320 |
| CHEMBL ID | 3544688 |
| SCHEMBL ID | 7715643 |
| MeSH ID | M0529101 |
Synonyms (22)
| Synonym |
|---|
| 7-o-demethyl rapamycin |
| 7-o-demethyl rapammune |
| 151519-50-5 |
| 7-o-demethyl cypher |
| CJ-12263 , |
| SCHEMBL7715643 |
| unii-2719uahua8 |
| 16-o-demethylsirolimus |
| CHEMBL3544688 |
| rapamycin, 7-o-demethyl- |
| HY-123691 |
| CS-0084352 |
| 7-o-demethylrapamycin |
| 16-o-demethylrapamycin |
| novolimus |
| n-929-89b |
| 2719UAHUA8 , |
| 7-o-demethylsirolimus |
| cj12263 |
| cj 12263 |
| novolimus (80%) |
| 7-o-demethyl rapamycin (~80%) |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "In this FIM study, implantation of the novolimus-eluting stent was proven to be feasible, safe and elicited minimum neointimal proliferation." | ( EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. Abizaid, A; Bhat, V; Costa, JR; Costa, R; Feres, F; Fitzgerald, P; Maia, F; Meredith, L; Ormiston, J; Seixas, AC; Siqueira, D; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF; Yan, J, 2008) | 0.86 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (27)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 22 (81.48) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.90) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (17.86%) | 5.53% |
| Reviews | 3 (10.71%) | 6.00% |
| Case Studies | 3 (10.71%) | 4.05% |
| Observational | 1 (3.57%) | 0.25% |
| Other | 16 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||